Researchers have developed an experimental <a href="https://www.mid-day.com/lifestyle/health-and-fitness/article/structural-changes-in-blood-plasma-proteins-may-reflect-earliest-signs-of-alzheimers-disease-study-23622199" target="_blank" rel="nofollow noopener">Alzheimer</a>&rsquo;s drug. The compound, called FLAV-27, is designed to reset part of the cell&rsquo;s epigenetic machinery, the system that helps control which genes are turned on or off.&nbsp;
In animal models, that approach appeared to affect several hallmarks of the disease at once. The findings point to a possible new treatment.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

The compound, called FLAV-27, is designed to reset part of the cell’s epigenetic machinery, the system that helps control which genes are turned on or off

Breakthrough research unveils FLAV-27 for potential Alzheimer’s therapy

General Min Aung Hlaing becomes Myanmar’s new president

In animal models, that approach appeared to affect several hallmarks of the disease at once. The findings point to a possible new treatment.

Experimental Alzheimer’s drug FLAV-27 shows promise in resetting gene control

Trending Stories

Latest Photos

Latest Videos

Latest Web Stories

Mid-Day Fast

Home / News / World News / Article / Experimental Alzheimer’s drug FLAV-27 shows promise in resetting gene control